As retailers, payers and drugmakers expand access to GLP-1 therapies — with companies like Amazon and Walmart launching weight management programs — the drug class is reshaping both care delivery and pharmaceutical investment strategies.
That demand is influencing drug development, with obesity treatments overtaking oncology as the largest contributor to late-stage pipeline value for the first time in 16 years, according to a May 4 report from Deloitte.
Here are five notes from the report:
- Pipeline shift: Obesity drugs now account for about 25% of projected late-stage pipeline value, surpassing oncology at 20%, down from 26% in 2024.
- Returns tied to GLP-1s: Projected R&D returns rose to 7% in 2025, up from 5.9% in 2024. Excluding GLP-1 assets, returns fell to 2.9%.
- Revenue concentration: GLP-1 therapies represent about 38% of projected commercial inflows, reflecting growing reliance on a small group of high-value assets.
- Portfolio risk: About 54 assets — roughly 9% of the pipeline — are expected to generate about 70% of total risk-adjusted peak sales.
- Rising costs: The average cost to develop a drug increased to $2,671 million in 2025 from $2,229 million in 2024, raising pressure on drugmakers to sustain returns.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
